Bye Bye CFDA, Hello NMPA: China Regulatory Express
In the latest in a series of regulatory changes in China, the national drugs regulator has apparently been renamed the National Medical Products Administration (NMPA), while the country's essential drugs list has been expanded to include more oncology and pediatric drugs, which will be fully reimbursed.
You may also be interested in...
Cancer drug prices again on the chopping board in China, including for some products already affected, and more are coming.
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.